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Between July and October 2003, 121 clinical isolates of group A streptococci (GAS) were collected from a
London hospital and characterized by multilocus sequence typing (MLST) to determine the identity and
prevalence of clones circulating within this setting. A total of 39 sequence types (ST), of which 20 were
represented by a single isolate, were identified. The eight most prevalent clones among the 121 GAS were
ST117/emm81 (16%), ST39/emm4 (9%), ST62/emm87 (7%), ST28/emm1 (6%), ST36/emm12 (6%), ST46/emm22
(5%), ST334/emm82 (5%), and ST101/emm89 (4%). Compared to those in the MLST database (http://spyo-
genes.mlst.net), 12 (31%) of the 39 STs had not been previously identified, although 7 of these differed from
recognized STs at only a single locus, suggesting they were closely related to previously recognized strains.
Resistance to erythromycin and tetracycline was seen in 7 and 20% of isolates, respectively, with four isolates
resistant to both agents. GAS strains with higher (>80) emm types accounted for 45% of GAS isolates collected
during this study. Continuing GAS surveillance, using easily comparable methods, is important for detecting
changes in the character of disease-causing isolates.
Streptococcus pyogenes (group A streptococci [GAS]) is an
important pathogen associated in humans with a variety of
diseases, ranging from pharyngitis and impetigo to severe in-
vasive disease, including streptococcal toxic shock syndrome
and necrotizing fasciitis (10). In the late 1980s, concern about
GAS disease was heightened in many countries, as outbreaks
of more-severe clinical infection were reported (12). GAS in-
fections remain a significant public health problem. In 2003,
1,870 cases of bacteremia due to GAS in England, Wales, and
Northern Ireland were reported to the Health Protection
Agency’s Streptococcus and Diphtheria Reference Unit (20),
an incidence of 3.5 per 100,000 population.
Infections are largely treatable with appropriate antimicro-
bial therapy, although significant morbidity and mortality are
reported for invasive GAS disease (34). Penicillin, to which
GAS are uniformly susceptible, is the drug of choice for most
infections with this organism (6). Erythromycin is recom-
mended for treatment of penicillin-hypersensitive patients (6);
however, resistance to this agent is of increasing concern (9,
25), and tetracycline can be used as an alternative in areas
where resistance levels remain low (18). The development of
an effective vaccine to prevent throat infections, which have a
substantial economic cost and may occasionally lead to postin-
fectious sequelae and invasive disease (27), is highly desirable,
and a number of vaccine targets are being assessed, including
the highly variable immunogenic amino-terminal region of the
M protein (11, 22). However, more than 100 M protein sero-
types exist (16) and antibodies against this region offer type-
specific protection (23, 28), necessitating the construction of
multivalent vaccines by the use of hybrid proteins containing
epitopes from several different M serotypes.
To guide public health action policy and inform therapeutic
and preventative strategies for GAS infections, active and con-
tinuing surveillance is required to provide an accurate assess-
ment of disease burden and epidemiological data on the char-
acter of disease-causing isolates. There are a number of
programs in place for surveillance and characterization of in-
vasive GAS disease (34; A. Jafir, Abstr. 14th Eur. Congress
Clin. Microbiol. Infect. Dis., abstr. S263, 2004). Comparable
data on noninvasive isolates, which contribute a significant
disease burden, are likewise important.
Multilocus sequence typing (MLST) is a highly discrimina-
tory unambiguous method for identifying clusters of isolates
with identical or closely related genotypes and is highly suitable
for the analysis of bacterial populations for epidemiological
purposes (38). An MLST scheme has been developed for GAS
(14). In the present study, clones of GAS, within a collection of
clinical isolates predominantly from noninvasive disease, were
defined by MLST.
This work was presented at the 14th European Congress of
Clinical Microbiology and Infectious Diseases, Prague, Czech
Republic, 1 to 4 May 2004 (abstr. P1829).
Bacterial strains. A total of 121 GAS were analyzed in this
study. Strains were isolated from routine clinical specimens
submitted to the Diagnostic Bacteriology Laboratory of St.
Mary’s Hospital National Health Service Trust, London,
United Kingdom, over 4 months (July to October) during the
summer and fall of 2003. Only one isolate per patient was
included in the study. Isolates were recovered from specimens
taken from hospitalized patients (n  11) and outpatients
attending emergency rooms (n 38), specialty outpatient clin-
ics (n  7), and general practitioners (n  48). The origins of
17 isolates were not specified. The majority (114 of 121; 94.2%)
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of GAS in this study were isolated from noninvasive speci-
mens, including throat (n  47), wound (n  23), skin (n  7),
genital (n  8), eye, ear, nose, and pus swabs. The remaining
seven isolates were recovered from blood. Of these, three were
from patients with bacteremia secondary to wound infection,
three were isolated from injecting drug users, and one was of
unknown etiology. No patients presented with severe invasive
infections or postinfectious complications such as necrotizing
fasciitis, toxic shock-like syndrome, rheumatic fever, or post-
streptococcal glomerulonephritis during the study.
MLST. Internal fragments of seven housekeeping genes
were amplified by PCR and subjected to nucleotide sequence
determination as previously described (14). Distinct allele
numbers were assigned to every unique gene sequence, and
each isolate was given a seven-integer allelic profile. Isolates
with identical allelic profiles were assigned to the same se-
quence type (ST). A database containing the allelic profiles of
GAS isolates and associated epidemiological data is main-
tained at http://spyogenes.mlst.net. Isolates with STs differing
at only one of the seven loci (single-locus variants; [SLVs])
were considered to be closely related (17).
emm sequence typing. The DNA sequence of the 5 end of
the emm gene was obtained as previously described (5). An
emm type and a subtype were assigned according to exact
150-bp sequences as described at a Centers for Disease Con-
trol website (http://www.cdc.gov/ncidod/biotech/strep/em-
mtypes.html). A unique emm type is defined as having 92%
sequence identity to any other known emm type over the 90
bases encoding the N-terminal 30 residues of the mature M
protein.
Antimicrobial susceptibility testing. All isolates were tested
by disk diffusion using 5-g erythromycin and 10-g tetracy-
cline disks (Oxoid, Basingstoke, United Kingdom) on Iso-Sen-
sitest agar with 5% defibrinated horse blood in accordance
with British Society for Antimicrobial Chemotherapy guide-
lines (3).
Results and discussion. We report the results of emm se-
quence typing and MLST of a collection of GAS isolates re-
covered from clinical specimens at a London hospital. From
the 121 GAS isolates, representing 36 distinct emm types, 39
STs were resolved (Table 1). Eight STs account for 57.9% of
GAS isolates, while 20 STs are represented by a single isolate.
The isolation of multiple GAS of a single clone did not appear
to be the result of an outbreak, as isolates were generally
recovered from specimens taken at various times throughout
the study and from patients presenting in different locations.
As a result of comparisons performed using the present S.
pyogenes database at http://spyogenes.mlst.net (identification
numbers 1 to 682), 12 new STs were described in this study
(although 7 of these are SLVs of previously identified STs)
(Table 2).
There was a strong correlation between emm and ST within
this set of isolates, with the majority (84.6%) of STs associated
with a single and distinct emm type. Three emm types were
found in association with multiple STs (Table 1). emm22 was
associated with a pair of SLVs (ST46 and ST328). emm82 was
associated with two STs (ST314 and ST334), which are SLVs of
ST26, and both are therefore likely to be descended from the
latter ST. Only emm103 was found in association with two
highly divergent STs (ST311 and ST327, which differ at six of
the seven loci). Similar concordance has been noted in other
local epidemiological studies using both emm sequence typing
and MLST (30, 35, 40).
The most prevalent clone isolated in the summer of 2003 was
ST117/emm81. The 19 ST117/emm81 isolates were recovered
from a variety of specimens, including blood (n 4), wound (n
 5), skin (n  2), eye (n  2), ulcer (n  2), throat (n  1),
and unspecified (n  3) swabs. A study of emm types present
in the United Kingdom during the 1980s reported emm81 as an
important cause of skin disease (8). In this study, 30 isolates
(represented by 18 STs), having been recovered from skin and
wound swabs, were associated with skin infections. ST117/
emm81 was the most prevalent (23.3%; 7 of 30) clone associ-
ated with skin isolates, suggesting that this strain continues to
be common in United Kingdom GAS skin infections. ST117/
emm81 GAS have also been recovered from aboriginal Aus-
tralians (30), with whom skin infection is common. The finding
of ST117/emm81 as an important clone in United Kingdom
GAS infections may be reflective of the time period in which
this study was conducted. It would be of interest to determine
whether this clone was similarly prevalent during winter
months.
In the United Kingdom, invasive GAS infection associated
with injecting drug use appears to be increasing (13). Three
isolates in this study, two ST117/emm81 clones and one ST62/
emm87 clone, were obtained from the blood of injecting drug
users. It is probable that skin or mucosal lesions related to drug
injection served as a portal of entry to the bloodstream in these
instances (29). There is evidence to suggest that high-risk be-
havior such as sharing of needles and the resultant multiple
handling of drug paraphernalia, rather than contaminated
batches of drug, is contributing to the increase in GAS infec-
tion in this group (13). That infections in users in this study
were caused by commonly circulating clones is supportive of
this suggestion.
The most common GAS clones in this study, in order of
decreasing prevalence, were ST117/emm81, ST39/emm4, ST62/
emm87, ST28/emm1, ST36/emm12, ST46/emm22, ST334/
emm82, and ST101/emm89 (Table 1). The Health Protection
Agency Streptococcus and Diphtheria Reference Unit has re-
cently reported preliminary results from the first year of en-
hanced surveillance of invasive GAS infections in the United
Kingdom (19). While MLST analysis has not been performed,
M serotyping results indicate that M1, M3, M87, M89, M12,
M83, and M5 were important causes of invasive disease in the
United Kingdom in 2003. It is clear that, as in this study, strains
with higher (80) emm types account for a significant propor-
tion of isolates.
The emergence of GAS strains with higher emm types as a
significant cause of disease may have important ramifications
for emm-directed vaccine strategies. The hexavalent vaccine,
containing N-terminal M protein fragments of serotypes 1, 3, 5,
6, 19, and 24, presently in phase 1 clinical trials (26) would be
active against only 13.2% of noninvasive isolates in this study
and none of the invasive isolates. A 26-valent M protein vac-
cine under development includes N-terminal peptides covering
39.7% of isolates in this study (Table 1), although it may
provide protection against additional M types (22). The sero-
types in this expanded-multivalent vaccine were selected, in
part, for their frequency in uncomplicated pharyngitis (22) and










include serotypes for 86% of North American pharyngeal iso-
lates (37). When only the isolates recovered from throat swabs
in this study (n  47) are considered, the 26-valent vaccine
contains epitopes for 26 (55.3%) of the throat GAS. Variability
in N-terminal M protein sequence, as determined by the pres-
ence of multiple emm subtypes, was noted within three MLST-
defined clones (ST46, ST99, and ST247) in this study (Table 1).
It is unknown what, if any, impact this variability might have on
vaccine efficacy and whether M-generated antibodies provide
protection to all subtypes of a given emm type.
Resistance to erythromycin and tetracycline was seen in 6.6
and 19.8% of isolates, respectively, with four isolates resistant
to both agents (Table 1). This is similar to levels reported
among invasive United Kingdom isolates (20). In this study the
appearance of resistant isolates was not associated with par-
ticular clones. Indeed, resistant isolates included strains with
19 distinct STs. Furthermore, for a number of erythromycin
resistance-associated STs, susceptible clones (ST36, ST46, and
TABLE 1. Prevalence of MLST-defined clones within 121 GAS from a London hospital
Sequence
type emm type emm subtype(s)
No. of
isolates (%)
No. of isolates resistant to:
Erythromycin Tetracycline
ST117 81 81.0 19 (15.7) 5
ST39 4 4.0 11 (9.1)
ST62 87 87.0 9 (7.4)
ST28 1b 1.0 7 (5.8) 1
ST36 12b 12.0 7 (5.8) 1c 1
ST46 22a,b 22.0, 22.2 6 (5.0) 1
ST334 82a 82.0 6 (5.0)
ST101 89b 89.0 5 (4.1)
ST52 28b 28.0 4 (3.3)
ST63 77b 77.0 4 (3.3) 1c 3
ST99 5b 5.3, 5.37, 5.38, 5.39 4 (3.3)
ST315 3b 3.1 4 (3.3)
ST253 78 78.0 3 (2.5)
ST5 83 83.1 2 (1.6) 2
ST55 2b 2.0 2 (1.6)
ST89 94 94.1 2 (1.6) 2c 2
ST150 75b 75.0 2 (1.6) 2
ST247 68 68.1, 68.3 2 (1.6) 1
ST328 22a,b 22.0 2 (1.6)
ST3 33b 33.0 1 (0.8) 1
ST75 9 9.0 1 (0.8)
ST100 55 55.0 1 (0.8) 1
ST166 st463 st463.0 1 (0.8) 1
ST167 118 118.0 1 (0.8)
ST168 120 120.0 1 (0.8)
ST176 58 58.0 1 (0.8)
ST284 stNS1033 stNS1033.0 1 (0.8) 1
ST285 95 95.0 1 (0.8) 1
ST297 63 63.3 1 (0.8) 1
ST307 100 100.0 1 (0.8)
ST308 27G 27G.0 1 (0.8)
ST311 103a 103.0 1 (0.8) 1
ST314 82a 82.0 1 (0.8)
ST327 103a 103.0 1 (0.8)
ST331 73 73.0 1 (0.8)
ST333 8 8.0 1 (0.8) 1
ST336 85 85.1 1 (0.8) 1
ST337 66 66.0 1 (0.8)
ST364 93 93.0 1 (0.8) 1
a emm types associated with multiple STs.
b emm types represented in the 26-valent vaccine (22) which includes the specific 5 sequences of emm types 1, 1.2, 2, 3, 5, 6, 11, 12, 13, 14, 18, 19, 22, 24, 28, 29,
33, 43, 59, 75, 76, 77, 89, 92, 101, and 114.
c Also resistant to tetracycline.
TABLE 2. Allelic profiles of new STs associated with this report
Sequence
type
Allelic profile SLV in
MLST
databaseagki gtr murI mutS recP xpt yqiL
ST247 11 9 1 7 2 8 3 No
ST284 2 66 1 52 75 2 12 No
ST285 86 6 8 3 9 3 1 ST14
ST307 1 31 61 40 60 8 42 No
ST311 4 2 2 51 1 59 1 No
ST314 4 65 21 16 17 3 1 ST26
ST315 2 6 8 5 2 3 53 ST15
ST328 9 8 58 1 1 3 4 ST46
ST333 51 3 8 25 33 3 27 No
ST334 84 2 21 16 17 3 1 ST26
ST337 8 7 8 49 9 3 1 ST44
ST364 2 2 9 13 2 14 55 ST10
a SLVs (single-locus variants) differ from another ST at only one of the seven
MLST loci and are considered to be closely related. The current S. pyogenes
MLST database (http://spyogenes.mlst.net) includes 678 isolates, representing
273 STs.










ST63) were also identified in this study. These findings suggest
that the emergence of erythromycin resistance in London GAS
resulted from acquisition of resistance genes by susceptible
isolates present in the circulating population rather than by the
introduction of a resistant clone into the population and clonal
expansion of the resistant clone. Similar findings were noted
for tetracycline-resistant isolates.
Erythromycin-resistant MLST-defined clones of ST36, ST46,
ST63, and ST150 GAS have previously been reported in Ger-
many (35) and Poland (40). At this point it is unclear whether
these resistant clones are spreading throughout Europe or
whether this represents multiple acquisitions of resistance
genes by the same prevalent STs. That scenario is supported by
the finding of ST36 clones carrying either mefA or ermB resis-
tance genes and ST63 GAS harboring mefA, ermB, or ermTR
genes (35, 40).
Surveillance data suggest that a small number of GAS clones
account for the majority of disease, although country-to-coun-
try and year-to-year fluctuation in the relative proportions of
the most common types occur (1, 7, 15, 19, 21, 24, 31, 34, 37,
41). The emergence of strains with higher emm types has, in
part, reshaped the overall picture of GAS infection in the
United Kingdom in recent years. The introduction of a vaccine,
particularly if it targets only a subset of GAS isolates (for
example, the most common M serotypes), may have an impact
on the bacterial population (39). The potential effects of vac-
cination on the incidence of non-vaccine serotype disease are
unknown. Ongoing surveillance is required to monitor epide-
miological changes in GAS character that may result from the
appearance of more-virulent or -resistant clones. It has been
proposed that emergence and global dissemination of highly
virulent strains may be responsible for the notable increase in
severe M1 disease in 1980s (32), although the factors mediat-
ing the increased virulence are unclear. Phage-encoded Sda1
streptodornase is present in post-1980s M1 GAS, but not in
older isolates (4), and likewise, phage-encoded SpeA exotoxin
is apparently more frequently associated with post-1980s iso-
lates (32, 33). The acquisition of resistance genes by suscepti-
ble clones is of concern, as proliferation of resistant clones may
result from selection imposed by antibiotic use (2, 36). Studies
to examine the long-term consequences of resistance on pop-
ulation structure should ideally include both susceptible and
resistant isolates.
In summary, the present study describes the GAS clones
circulating in London during the summer of 2003. This work
provides useful comparative data for future studies.
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